FOLH1 and Bone marrow hypocellularity: Patients whose prostate cancer has spread throughout the bone marrow and has induced bone marrow failure may not be good candidates for 177Lu-PSMA due to the extended route length of 177Lu, which may cross 20 to 60 cells resulting in bone marrow failure [42].